KOSDAQBiotech & Pharma298060

Poongjeon Pharmacy

₩2,195▲ 1.86%2026-11-18 close
Market Cap
₩21.2B
Turnover
₩51,313,194
Volume
20K
Shares out.
9.6M
PER
—
PBR
0.7×
EPS
-₩692
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Revenue has grown, but quarterly losses persist

Acquisition-driven revenue reached KRW 23.8 billion in 2025, but operating losses have run for five straight quarters since Q3 2025, and net losses attributable to controlling shareholders total KRW 5.69 billion over the last four quarters.

  1. 1

    The business now spans three units: bio, cosmetics and pharmaceutical wholesale. The wholesale acquisition came in July 2025, the cosmetics purchase in September 2025, and the merger took effect in April 2026.

  2. 2

    Revenue in 2025 was KRW 23.8 billion, up 2,790.3% from the prior year, and net income attributable to controlling shareholders of KRW 203 million was a swing to profit. Press reports put a bargain-purchase gain of about KRW 1.8 billion in the 2025 accounts, so part of that profit is one-off in nature.

  3. 3

    Quarterly revenue peaked at KRW 15.2 billion in Q1 2026 and fell in Q2 and Q3, while the operating loss narrowed to KRW 560 million in Q3 2026.

  4. 4

    A KRW 2 billion third-party share allotment and a KRW 2 billion convertible bond purchase by an asset manager were disclosed in September 2026, and a third-party issue of 1.2 million shares at KRW 2,500 each was decided in October, with listing scheduled for November 26, 2026.

  5. 5

    Because the last four quarters show net losses, PER cannot be calculated, and the price-to-book ratio sits below 1x.

02

Business structure

Poongjeon Pharmacy went public on KOSDAQ in 2020 as a technology growth company built on stem cell research, and since 2025 it has widened its business into three units: bio, cosmetics and pharmaceutical distribution.

In July 2025, SCM Lifescience acquired 100% of the pharmaceutical wholesaler Poongjeon Pharmacy for about KRW 8.2 billion, and that wholesale company was absorbed into the parent through a merger effective April 1, 2026.

In September 2025 the group bought 100% of a cosmetics company, which strengthened the cosmetics unit.

The bio unit centers on stem cell therapy pipelines, with a Phase 1/2 clinical trial plan approved for moderate-to-severe atopic dermatitis, patents on stem cell culture methods, and joint research and licensing arrangements with overseas institutions.

The cosmetics unit draws on a patent for a cosmetic composition containing stem cell conditioned medium, and it has expanded abroad through an exclusive Japanese distribution right for skincare products and an exclusive Vietnamese supply agreement.

The wholesale unit is the main driver of consolidated revenue, but wholesale carries low margins relative to its sales volume, so higher revenue does not automatically translate into better profitability.

The company has stated that the wholesale acquisition aimed to expand new businesses and create synergies with existing operations. Because the bio unit is centered on pipelines still in clinical development, its contribution to reported revenue appears limited for now.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩10.5B-₩900M−8.9%
2025Q4₩12.1B-₩1.2B−9.7%
2026Q1₩15.2B-₩1.5B−9.7%
2026Q2₩12B-₩1B−8.2%
2026Q3₩10.4B-₩600M−5.4%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩400M-₩12.6B-₩22.9B−3176.6%−93.5%34.7%
2023₩700M-₩13B-₩24B−1868.3%−117.0%24.1%
2024₩800M-₩11.3B-₩12.4B−1371.0%−87.3%63.4%
2025₩23.8B-₩4.5B₩200M−19.0%0.6%44.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-14

04

Earnings analysis

Annual revenue rose from KRW 396 million in 2022 to KRW 696 million in 2023 (up 75.7% year on year) and KRW 825 million in 2024 (up 18.6%), then reached KRW 23.8 billion in 2025 (up 2,790.3%), growing for three consecutive years from 2023 through 2025.

Within the 2022 to 2025 span, 2025 was the largest year and 2022 the smallest. Related sources attribute the 2025 jump to wholesale sales added through the merger and growth in cosmetics.

Operating losses were KRW 12.6 billion in 2022 and widened to KRW 13 billion in 2023, then narrowed to KRW 11.3 billion in 2024 and KRW 4.53 billion in 2025, with losses in all four years. The same sources cite higher R&D spending and one-off costs as the background to the 2025 operating loss.

The operating margin improved from -3,176.6% in 2022 to -1,868.3% in 2023, -1,371.0% in 2024 and -19.0% in 2025. Net losses attributable to controlling shareholders were KRW 22.9 billion in 2022, KRW 24 billion in 2023 and KRW 12.4 billion in 2024, before a return to profit in 2025 with net income of KRW 203 million.

Press reports describe a bargain-purchase gain of about KRW 1.8 billion recognized in the 2025 accounts, so part of the 2025 profit is one-off.

Equity totaled KRW 36.1 billion at end-2025, all attributable to controlling shareholders, with total liabilities of KRW 15.9 billion, and the debt ratio fell from 63.4% in 2024 to 44.1% in 2025.

Operating cash flow was -KRW 11.2 billion in 2022, -KRW 12.1 billion in 2023, -KRW 10.1 billion in 2024 and -KRW 5.3 billion in 2025, with outflows in every year and the 2025 outflow the smallest.

Quarterly revenue was KRW 10.5 billion in Q3 2025, KRW 12.1 billion in Q4 2025 (up 14.7% from the prior quarter) and KRW 15.2 billion in Q1 2026 (up 26.1%), then fell to KRW 12 billion in Q2 2026 (down 21.3%) and KRW 10.4 billion in Q3 2026 (down 13.1% quarter on quarter and down 1.2% year on year), a two-quarter decline.

Operating losses have run for five consecutive quarters since Q3 2025, when the loss was KRW 940 million, reaching KRW 1.48 billion in Q1 2026 before narrowing to KRW 986 million in Q2 and KRW 560 million in Q3 2026.

Net income attributable to controlling shareholders was KRW 936 million in Q3 2025 and KRW 804 million in Q4 2025, then turned into a net loss of KRW 1.83 billion in Q1 2026, KRW 3.94 billion in Q2 and KRW 719 million in Q3, a three-quarter losing streak. The last four quarters total a net loss of KRW 5.69 billion attributable to controlling shareholders.

05

Industry analysis

Pharmaceutical wholesale is a large-sales, low-margin business, so Poongjeon Pharmacy's revenue growth does not automatically translate into better profitability.

The domestic drug wholesale market is competitive and centered on large wholesale companies, and Poongjeon Pharmacy grew its revenue by merging a mid-sized wholesaler founded in 1995.

The cosmetics unit has seen selling and administrative expenses rise alongside its expansion, and the brand value and goodwill acquired must be proven through reported results.

The bio unit is centered on stem cell therapy pipelines in clinical development, so its contribution to group revenue appears limited until commercial sales emerge.

Compared with listed peers such as Samsung Biologics, Alteogen and Celltrion, which have production capacity or technology export track records, the scale and earnings structure gap is wide.

Across the pharmaceutical and bio sector, share prices tend to react sharply to clinical results and licensing announcements, so volatility can rise around those events. The overseas distribution deals in cosmetics and skincare are generally read as expanding sales channels into Japan and Vietnam.

The company's market capitalization is in the small range among KOSDAQ-listed companies, which limits direct comparison with sector average multiples.

06

Outlook

The next periodic report is the 2026 annual report, and the Q4 2026 and full-year results will be finalized around the end of March 2027, the filing deadline 90 days after year-end.

The 1.2 million new shares scheduled for listing on November 26, 2026 are expected to be held in custody with the Korea Securities Depository for one year.

In September 2026, a technology investment fund acquired 796,812 common shares in a third-party allotment for KRW 2 billion, and in the same month an asset manager acquired 600,240 convertible bonds worth KRW 2 billion.

At the extraordinary shareholders meeting on September 30, 2026, an amendment to part of the articles of incorporation was approved by special resolution.

On the business side, quarterly revenue has declined since Q2 2026, so how well wholesale sales hold up quarter to quarter after the merger is the next point to watch.

The operating loss narrowed to KRW 560 million in Q3 2026, but net losses attributable to controlling shareholders have persisted for three quarters, so the timing of a return to profit is the central point to track.

In cosmetics, the results of the company acquired in September 2025 and whether the Japan and Vietnam distribution deals show up in revenue are the items to confirm. In bio, pipeline progress and disclosures of licensing agreements are the next items to track.

The Q1 2027 quarterly report, due around mid-May 2027, will be the first period that can be compared with the KRW 15.2 billion revenue of Q1 2026.

07

Valuation

PER
—
PBR
0.7×
ROE
-18.4%
EPS
-₩692
BPS
₩3,275
Dividend per share
₩0

Because net losses attributable to controlling shareholders total KRW 5.69 billion over the last four quarters, PER cannot be calculated, and no earnings-based multiple comparison is possible at present. PBR sits below 1x, and market capitalization is smaller than total equity of KRW 36.1 billion at the end of 2025.

Nearly all equity is attributable to controlling shareholders, so a book-value comparison is meaningful, but how quickly those assets turn into earnings during continued operating losses shapes what that comparison means. The dividend yield is below the sector average.

The 2025 return to profit includes one-off accounting gains, which limits what earnings-based metrics say about the core business. Third-party share issues in September and October 2026 are increasing the share count, which changes the base for comparing market value and per-share figures.

The narrowing of the operating margin to -19.0% in 2025 shows the direction of improvement, but quarterly operating losses have continued through Q3 2026.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-14

08

Bull factors

Scale up, losses narrower

Revenue in 2025 was KRW 23.8 billion, up 2,790.3% from the prior year, and Q1 2026 revenue reached KRW 15.2 billion, the highest quarterly figure in the reported period.

The operating loss narrowed from KRW 11.3 billion in 2024 to KRW 4.53 billion in 2025, and in Q3 2026 it was KRW 560 million, below the KRW 986 million of Q2. Since the wholesale merger, the larger revenue base is the clearest change on the top line.

Equity base and lower leverage

Total equity at the end of 2025 was KRW 36.1 billion, all attributable to controlling shareholders. The debt ratio fell from 63.4% in 2024 to 44.1% in 2025, with total liabilities of KRW 15.9 billion. A 2025 share issue enlarged paid-in capital and widened the equity base, and PBR sits below 1x.

Three-unit operating structure

The cosmetics unit expanded through the company purchase in September 2025, and exclusive Japanese and Vietnamese distribution agreements for skincare products are widening overseas sales channels.

The bio unit has an approved Phase 1/2 trial plan for atopic dermatitis and joint research and licensing arrangements with overseas institutions. With three units operating together, segment disclosures will gradually show how much each contributes.

09

Bear factors

Net losses to shareholders persist

Net losses attributable to controlling shareholders have run for three straight quarters from Q1 through Q3 2026, with the Q2 loss of KRW 3.94 billion the largest. Operating losses are narrowing, but net losses remain, so the pace of improvement in the overall income structure is still limited.

Revenue turns lower

Revenue peaked at KRW 15.2 billion in Q1 2026 and then fell to KRW 12 billion in Q2 and KRW 10.4 billion in Q3, a two-quarter decline. Q3 revenue was down 1.2% year on year, so the merger effect has not yet produced year-on-year growth.

Because wholesale is a low-margin business, a smaller revenue base offers limited cushion for earnings recovery.

One-off gains and reliance on share issues

Press reports describe a bargain-purchase gain of about KRW 1.8 billion as part of the 2025 profit. In September and October 2026 the company raised funds through a third-party share allotment and a convertible bond purchase, and the 1.2 million shares issued in October were priced at KRW 2,500 each. Because the company depends on external funding, the additional share supply dilutes existing shareholders.

10

Risk factors

Financing and dilution

Third-party share issues and a convertible bond purchase in September and October 2026 brought in funds, but listing 1.2 million new shares increases the share count.

Those new shares are subject to a one-year custody lock-up, which limits near-term float, but conversion of the convertible bonds would add further dilution. The funding need is tied to the size of the operating losses.

Wholesale margins and merger integration

Wholesale carries thin margins, so a revenue decline or higher selling and administrative costs could delay further narrowing of the operating loss. Rising selling and administrative expenses from the cosmetics expansion add pressure in the same direction.

Running three units together still requires the company to prove its customer management and cost control in reported results.

Uncertainty in the bio pipeline

The stem cell therapy business is centered on pipelines still in clinical development, so results may vary widely with trial outcomes and regulatory timing. Licensing and distribution agreements are hard to reflect in earnings until contract size and milestone achievement are disclosed.

Because part of the 2025 profit was a one-off accounting gain, the durability of core-business earnings is also hard to judge.

11

What to watch next

  1. November 26, 2026

    Scheduled listing date for the 1.2 million shares issued in a third-party allotment. The new shares are expected to be held in custody for one year, which sets the baseline for how the tradable float changes after listing.

  2. Late March 2027

    Filing deadline for the 2026 annual report. The Q4 and full-year 2026 results are finalized here, showing the full-year operating margin with the merger effect included and the margin structure of the wholesale unit.

  3. Mid-May 2027

    Filing period for the Q1 2027 quarterly report. It can be compared with the KRW 15.2 billion revenue of Q1 2026, which shows how well wholesale sales hold up after the peak.

12

Overall view

Poongjeon Pharmacy has shifted from a stem cell-based bio developer to a diversified structure that adds pharmaceutical wholesale and cosmetics, and 2025 revenue expanded to KRW 23.8 billion.

The 2025 return to profit, with net income attributable to controlling shareholders of KRW 203 million, included a bargain-purchase gain of about KRW 1.8 billion, so one-off factors come with that result.

In 2026, quarterly revenue peaked at KRW 15.2 billion in Q1 and then declined for two quarters, and the operating loss narrowed to KRW 560 million in Q3 2026, but operating losses have continued for five consecutive quarters.

Net losses attributable to controlling shareholders total KRW 5.69 billion over the last four quarters. Share issues and a convertible bond purchase in September and October 2026 brought in funds and widened the equity base, but the listing of new shares raises the share count and adds dilution.

On valuation, PER cannot be calculated and PBR sits below 1x, while the dividend yield is below the sector average.

Strengths include revenue growth, a narrower operating loss and a lower debt ratio, while weaknesses include continued net losses to controlling shareholders, a revenue decline after the Q1 peak and reliance on share issues. The next checkpoint is the operating margin and the wholesale margin structure shown in the 2026 annual report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. thevc.kr
  2. saramin.co.kr
  3. comp.fnguide.com
  4. medicopharma.co.kr
  5. m.yakup.com
  6. goinsider.kr
  7. dealsite.co.kr
  8. vegannews.co.kr
  9. pharmnews.com
  10. awakeplus.co.kr
  11. digitaltoday.co.kr
  12. judal.co.kr
  13. eugenefn.com
  14. judal.co.kr
  15. judal.co.kr
  16. judal.co.kr
  17. judal.co.kr

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis